CorMedix (CRMD) Projected to Post Earnings on Thursday

Key Points

• CorMedix (CRMD) is set to announce its Q2 2025 earnings on August 13, with analysts predicting earnings of $0.17 per share and revenue of $29.88 million.
• Previous earnings results showed a reported EPS of $0.30, exceeding the estimate of $0.25, while revenue was $39.08 million, surpassing expectations.
• Analysts have varied ratings for CorMedix, with recent target price updates raising it to as high as $20.00, while a few have downgraded their ratings to "hold."

CorMedix (NASDAQ:CRMD - Get Free Report) will likely be posting its Q2 2025 quarterly earnings results before the market opens on Thursday, August 7th. Analysts expect the company to announce earnings of $0.20 per share and revenue of $29.88 million for the quarter.

CorMedix (NASDAQ:CRMD - Get Free Report) last released its quarterly earnings results on Thursday, August 7th. The company reported $0.28 earnings per share for the quarter, topping the consensus estimate of $0.20 by $0.08. The business had revenue of $39.74 million for the quarter, compared to the consensus estimate of $29.88 million. CorMedix had a net margin of 20.81% and a return on equity of 22.57%. The company's quarterly revenue was up 4830.1% on a year-over-year basis. During the same period last year, the firm earned ($0.25) earnings per share. On average, analysts expect CorMedix to post $0 EPS for the current fiscal year and $1 EPS for the next fiscal year.

CorMedix Price Performance

Shares of NASDAQ:CRMD traded down $0.48 during midday trading on Friday, hitting $10.33. The company had a trading volume of 8,503,029 shares, compared to its average volume of 1,855,753. CorMedix has a 12-month low of $3.61 and a 12-month high of $17.43. The company has a fifty day moving average of $12.52 and a two-hundred day moving average of $10.81. The company has a market cap of $700.63 million, a price-to-earnings ratio of 46.96 and a beta of 1.71.

Analysts Set New Price Targets

A number of brokerages have commented on CRMD. Needham & Company LLC upped their price target on CorMedix from $15.00 to $20.00 and gave the stock a "buy" rating in a research report on Tuesday, June 24th. D. Boral Capital lowered shares of CorMedix from a "buy" rating to a "hold" rating in a report on Monday, June 30th. HC Wainwright lowered their price target on shares of CorMedix from $20.00 to $17.00 and set a "buy" rating on the stock in a report on Friday. D Boral Capital lowered shares of CorMedix from a "strong-buy" rating to a "hold" rating in a research report on Monday, June 30th. Finally, Royal Bank Of Canada raised shares of CorMedix from an "outperform" rating to a "moderate buy" rating and increased their price objective for the stock from $13.00 to $17.00 in a research note on Friday, June 20th. Three equities research analysts have rated the stock with a hold rating, five have given a buy rating and one has given a strong buy rating to the company's stock. Based on data from MarketBeat, CorMedix currently has a consensus rating of "Moderate Buy" and a consensus target price of $16.71.

Hedge Funds Weigh In On CorMedix

An institutional investor recently raised its position in CorMedix stock. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its position in shares of CorMedix Inc (NASDAQ:CRMD - Free Report) by 4.7% during the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 35,987 shares of the company's stock after acquiring an additional 1,631 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. owned approximately 0.05% of CorMedix worth $222,000 as of its most recent filing with the Securities and Exchange Commission (SEC). Institutional investors own 34.18% of the company's stock.

CorMedix Company Profile

CorMedix Inc, a biopharmaceutical company, focuses on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases in the United States. Its lead product candidate is DefenCath, an antimicrobial catheter lock solution to reduce the incidence of catheter-related bloodstream infections in adult patients with kidney failure.